Gratuita da 29,90 con consegna a domicilio (BRT, GLS, Amazon Shipping)
Our approach centers on Semaglutide, a GLP-1 receptor agonist clinically proven to help with weight loss in adults with obesity or overweight, alongside lifestyle support from qualified medical professionals
What science actually says Clinically reviewed by Dr
One study also suggested there could be a connection between semaglutide use and increased risk for non-arteritic anterior ischemic optic neuropathy (NAION), a blinding eye disease
427 Epidemiological studies estimate that approximately 20% of the general population has genetically elevated Lp(a) levels, predisposing them to a higher lifetime risk of ASCVD
The potential for these side effects, without the mitigating health benefits of addressing obesity or type 2 diabetes, becomes a significant concern